← Ashland Global overview

Ashland Global vs Axalta Coating Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ashland Global Holdings Inc (ASH)

Q3 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

August 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Latest
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Axalta Coating Systems Ltd (AXTA)

Q3 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

August 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

Latest
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.